Article

The evaluation of targeted radionuclide therapies and radio sensitising agents in malignant melanoma

2018-01-01

Abstract excerpt

Introduction: Malignant melanoma is highly resistant to conventional cancer therapies, characterised by a broad spectrum of radio resistance combined with a low response to chemotherapeutics. This state is compounded by inadequate dose delivery of conventional radiotherapy options. A targeted approach to radiotherapy exploiting native features of the melanoma cells such as melanin may in combination with radiosens...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2588fb22-d19e-5302-b733-cca6ddb85c5a
DOI: 10.48730/ae47-e942

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

The evaluation of targeted radionuclide therapies and radio sensitising agents in malignant melanomaDOI 10.48730/ae47-e942Read

Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52.Semantic proximity Read

Mesenchymal Neuroblastoma Cells Lack Critical Transporters for mIBG Uptake and May Evade Detection and TherapySemantic proximity Read

Targeted Therapy Innovations for Melanoma.Semantic proximity Read

Targeted therapeutic strategies for melanoma.Semantic proximity Read

Towards the targeted therapy of melanoma.Semantic proximity Read

Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities.Semantic proximity Read

Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain MetastasesSemantic proximity Read

Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.Semantic proximity Read